Compare Fidelity National Information Servcs Inc (FIS) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Eli Lilly And Co — how do they compare? Fidelity National Information Servcs Inc trades at $42.11 (market cap $21.24B), while Eli Lilly And Co trades at $1,176.68 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 48.5× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays the higher dividend (4.09%). Which is the better fit depends on your goals.
| FIS | LLY | |
|---|---|---|
Market Cap | $21.24B | $1.03T |
Sector | Technology | Health |
52-Week High | $81.94 | $1.24K |
52-Week Low | $37.72 | $625.65 |
Enterprise Value | $41.63B | $1.07T |
Dividend Yield | 4.09% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $42.02, up 3.54% today, with a bearish technical signal but strong analyst support. The company shows improving fundamentals with Q1 2026 EPS beating expectations and a consensus price target of $52.57. Recent news highlights innovation in AI and cloud banking, though cash flow trends and debt levels warrant monitoring.
The outlook is cautiously optimistic with potential upside from earnings growth and strategic initiatives, balanced by risks from competitive pressures and financial leverage. Investor sentiment is positive driven by analyst buy ratings and recent business wins, but volatility may persist near-term.
Eli Lilly (LLY) trades at $1,176.75, up 1.95% on the day, with strong fundamentals including a 31.66% net margin and consistent earnings beats. The stock shows a bearish technical signal near resistance at $1,177, while recent news highlights the $2.8 billion acquisition of AtaiBeckley to expand its mental health pipeline. Operating cash flow surged to $16.81 billion in 2025, supporting growth initiatives in obesity and Alzheimer's treatments.
Outlook remains positive with a $1.38K analyst price target and 73% buy ratings, but risks include competitive pressure in obesity drugs and high valuation multiples. Revenue growth of 65% in 2025 underscores momentum, though debt levels and acquisition integration pose challenges for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
